Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 4, 2025 • 7:00 AM ET

Date/Time Source News Release
10/30/2024 04:15 PM EDT GlobeNewswire Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
10/02/2024 04:05 PM EDT GlobeNewswire Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
09/03/2024 08:00 AM EDT GlobeNewswire Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
08/28/2024 08:00 AM EDT GlobeNewswire Processa Pharmaceuticals Provides Product Pipeline and Financial Update
08/19/2024 08:00 AM EDT GlobeNewswire Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
07/30/2024 08:00 AM EDT GlobeNewswire Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
07/17/2024 08:00 AM EDT GlobeNewswire Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
06/11/2024 08:20 AM EDT GlobeNewswire Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
05/06/2024 08:00 AM EDT GlobeNewswire Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
04/30/2024 08:00 AM EDT GlobeNewswire Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Page